The existing immune efficacy markers can be roughly divided into two categories: the first category is molecular markers related to tumor neoantigen load, such as microsatellite instability (MSI) or tumor mutational burden (TMB) increase; The second category is related to the tumor microenvironment (TME), including the expression of PD-L1 protein, tumor cell infiltration, and copy number variation (Cristescu et al., 2018). This evidence concerns the gene CD274 and neoplasm.